Hedge Fund - RA Capital Management

In a new filing with the Securities and Exchange Commission, Peter Kolchinsky's RA Capital Management disclosed a position in Derma Sciences Inc (NASDAQ:DSCI).

The practice of monitoring quarterly 13F filings has become more popular in recent years, which led to several exchange traded funds (ETFs) being launched.

With hedge funds having submitted their 13F filings for the third quarter, people at Insider Monkey are busy compiling the data necessary to identify the best investment opportunities in small-cap stocks...

Three prominent healthcare-focused funds that we track at Insider Monkey submitted filings with the SEC today, disclosing new or bulked up positions in three different healthcare stocks.

RA Capital Management, led by Peter Kolchinsky, has disclosed a massive new stake in California-based pharmaceutical company Zogenix, Inc (NASDAQ:ZGNX). A new filing with the U.S.

Steve Cohen’s Point72 Asset Management has initiated a new position in Inotek Pharmaceuticals Corporation (NASDAQ:ITEK).

Peter Kolchinsky's RA Capital Management recently filed its 13F with the SEC for the reporting period of June 30. Peter Kolchinsky started RA Capital Management after completing his Ph.D.

According to a recent filing with the Securities and Exchange Commission, Peter Kolchinsky's RA Capital has initiated a position in Alcobra Ltd (NASDAQ:ADHD), acquiring some 1.66 million shares of the...

The biotechnology industry is up by more than 50% over the last year, but these towering returns don't come without great risk and volatility.